CureVac is now part of the BioNTech Group
BioNTech successfully closed the acquisition of CureVac. With this, CureVac is now part of the BioNTech Group (Nasdaq: BNTX), a global next generation immunotherapy company …
BioNTech Announces Strategic Transaction to Acquire CureVac in …
Jun 12, 2025 · Following the closing of the transaction, CureVac’s operating subsidiary will become a wholly owned subsidiary of BioNTech. As part of this plan, BioNTech will integrate …
CureVac Announces Financial Results for the Fourth Quarter and …
Apr 10, 2025 · CureVac N.V. (Nasdaq: CVAC) (“CureVac”), a global biotech company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), …
CureVac veröffentlicht Finanzergebnisse für das zweite Quartal …
Aug 15, 2025 · CureVac (Nasdaq: CVAC) ist ein wegweisendes multinationales Biotech-Unternehmen, das im Jahr 2000 gegründet wurde, um die Technologie der Boten-RNA …
CureVac Announces Positive Phase 2 Interim Data from COVID-19 …
Jan 5, 2024 · CureVac (Nasdaq: CVAC) is a global biopharmaceutical company in the field of messenger RNA (mRNA) technology, with more than 20 years of expertise in developing, …
GSK and CureVac to Restructure Collaboration into New Licensing ...
Jul 3, 2024 · Since 2020, GSK and CureVac have worked together to develop mRNA vaccines for infectious diseases. Through this collaboration, GSK and CureVac currently have vaccine …
CureVac Announces Dosing of First Participant in Phase 2 Study of ...
Aug 1, 2023 · CureVac (Nasdaq: CVAC) is a global biopharmaceutical company in the field of messenger RNA (mRNA) technology, with more than 20 years of expertise in developing, …
About CureVac refined key underlying technologies that were essential to the production of mRNA vaccines against COVID-19, and is currently laying the groundwork for application of mRNA in …
CureVac Announces Financial Results for the First Quarter of 2025 …
May 20, 2025 · CureVac N.V. (Nasdaq: CVAC), a pioneering multinational biotech company developing a new class of transformative medicines based on messenger RNA (mRNA), today …
CureVac Receives U.S. FDA IND Clearance to Initiate Phase 1 …
Apr 7, 2025 · CureVac is leveraging mRNA technology, combined with advanced omics and computational tools, to design and develop off-the-shelf and personalized cancer vaccine …